Interleukin-18 in systemic lupus erythematosus: link with clinical symptoms and vascular atherosclerosis


Cite item

Full Text

Abstract

Aim. To examine correlation between IL-18 concentration, SLE manifestations and atherosclerotic vascular affection. Material and methods. We examined 162 SLE female patients (age 26-43 years, mean age 35 years, duration of SLE 28-204 months, mean duration 96.0 months) and 64 healthy controls (women aged 30.0-45.0 years, mean age 35.5 years). We analysed correlation between IL-18 concentration, SLE symptoms, classic risk factors for cardiovascular diseases, subclinical and clinical signs of atherosclerosis. Results. IL-18 in blood serum of SLE patients was much higher than in the control group (p < 0.00001). A positive correlation exists between IL-concentration and the disease activity by scale SLEDAI-2K, the level of antibodies to IgG cardiolipin, ESR, SLE, titers of antibodies to double-chain DNA, concentration of creatinin, urine, glucocorticoids dose taken by the patients at examination. In SLE patients with stomatitis, hematological, immunological disorders, a positive test for antinuclear factor, IL-18 was much higher than in patients without the above signs. No significant correlation was seen between IL-18 concentration, subclinical and clinical signs of atherosclerosis, of risk factors, there was a negative correlation between total cholesterol concentration, LDLP and HDLP cholesterol. Conclusion. In SLE patients a high IL-18 level reflects activity of the basic disease and is not related with vascular atherosclerosis.

Full Text

Интерлейкин-18 при системной красной волчанке: связь с клиническими проявлениями заболевания и атеросклеротическим поражением сосудов. - Цель исследования. Оценить связь концентрации интерлейкина (ИЛ) 18 с проявлениями системной красной волчанки (СКВ) и атеросклеротическим поражением сосудов. Материалы и методы. Обследованы 162 пациентки с СКВ в возрасте 35 (26-43) лет, продолжительность заболевания 96 (28-204) мес, и 64 условно здоровые женщины в возрасте 35,5 (30-45), которые составили контрольную группу. Анализировали взаимосвязь концентрации ИЛ-18 с проявлениями СКВ, классическими факторами риска развития сердечно-сосудистых заболеваний, субклиническими и клиническими признаками атеросклероза. Результаты. Уровень ИЛ-18 в сыворотке крови у больных СКВ был значительно выше, чем в контрольной группе (р < 0,00001). Выявлена положительная корреляция между концентрацией ИЛ-18 и активностью болезни по шкале SLEDAI-2K, уровнем антител к кардиолипину изотипа IgG, СОЭ, титрами антител к двуспиральной ДНК, концентрацией креатинина, мочевины, дозой глюкокортикоидов, принимаемой больными на момент обследования. У больных СКВ, имеющих на момент обследования стоматит, гематологические, иммунные нарушения и положительный тест на антинуклеарный фактор, концентрация ИЛ-18 была значительно выше, чем у пациентов без указанных признаков. Статистически значимой связи между концентрацией ИЛ-18, субклиническими и клиническими проявлениями атеросклероза не выявлено. Среди факторов риска обнаружена отрицательная корреляция с концентрацией общего холестерина, холестерина липопротеидов низкой и высокой плотности. Заключение. У пациентов с СКВ повышенный уровень ИЛ-18 отражает активность основного заболевания и не связан с атеросклеротическим поражением сосудов.
×

References

  1. Насонова В. А. Системная красная волчанка. М.: Медицина; 1972.
  2. Abu-Shakra М., Urowitz М. В., Gladman D. D. el al. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J. Rheumatol. 1995; 22: 1259-1264.
  3. Насонов E. Л. Антифосфолипидный синдром. M.: Литтерра; 2004.
  4. Urowitz М. В., Bookman А. А. M., Koehler В. Е. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 1976; 60: 221-225.
  5. Badui E., Garcia-Rubi D., Robles E. et al. Cardiovascular manifestations in systemic lupus erythematosus: prospective study in 100 patients. Angiology 1985; 36: 431-441.
  6. Gladman D. D., Urowitz M. B. et al. Morbidity in systemic lupus erythematosus. J. Rheumatol. 1987; 14: 223-226.
  7. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from defined population. Medicine (Baltimore) 1989; 68: 141-150.
  8. Petri M., Perez-Gutthann S., Spence D., Hochberg M. С. Risk factor for coronary arthery disease in patients with systemic lupus erythematosus. Am. J. Med. 1992; 93: 513-519.
  9. Heart-Holmes M., Baethege B. A., Broadwell L., Wolf R. E. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J. Rheumatol. 1995; 22: 450-454.
  10. Stahl-Hallengren C., Jonsen A., Nived O. et al. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 2000; 27: 685-691.
  11. Manzi S., Meilahn E. N., Rairie J. E. et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997; 145: 408-415.
  12. Asanuma Y., Oeser A., Shintani A. K. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003; 349: 2407-2415.
  13. Bruce I. N., Burns R. J., Gladman D. D., Urowitz M. B. A study of myocardial perfusion abnormalities in women with systemic lupus erythematosus. J. Rheumatol. 1998; 25: 72.
  14. Detrano R. C., Wong N. D., Doherty Т. M. et al. Coronary calcium docs not accurately predict near-term future coronary events in high-risk adults. Circulation 1999; 25: 2633-2638.
  15. Doberty N. E., Seigel R. J. Cardiovascular manifestations of systemic lupus erythematosus. Am. Heart J. 1985; 110: 1257-1265.
  16. Fukumoto S., Tsumagari Т., Kinjo M., Tanaka K. Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol. Jpn 1987; 37: 1-9.
  17. Hosenpud J. D., Montanaro A., Hart M. V. Myocardial perfusion abnormalities in asymptomic patients with systemic lupus erythematosus. Am. J. Med. 1984; 77: 286-292.
  18. Sella E. M., Sato E. I., Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthr. and Rheum. 2003; 48: 3168-3175.
  19. Solberg L. A., Strong J. P. Risk factors and atherosclerotic lesions. A review of autopsy studies. Atherosclerosis 1983; 3: 187-198.
  20. Okamaura H., Tsutsi H., Komatsu T. et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378: 88-91.
  21. Dinarello C. A. Interleukin-1. Cytokine Growth Factor Rev. 1997; 8: 253-265.
  22. Micallef M. J., Ohtsuki Т., Kohno K. et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 1996; 26: 1647-1651.
  23. Tsutsui H., Nakanishi K., Matsui K. et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 1996; 157: 3967-3973.
  24. Xu D., Chan W. L., Leung B. P. et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J. Exp. Med. 1998; 188: 1485-1492.
  25. Gerdes N., Sukhova G. K., Libby P. et al. Expression of interleukin (IL) - 18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells and macrophages: implications for atherogenesis. J. Exp. Med. 2002; 195: 245-257.
  26. Nakanishi K., Yoshimoto T., Tsutsui H. et al. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001; 19: 423-474.
  27. Puren A. J., Fantuzzi G., Gu Y. et al. Interleukin - 18 (IFN-γ-inducing factor) induces IL-8 and IL-1Β via TNFα production from non CD 14+ human blood mononuclear cells. J. Clin. Invest. 1998; 101: 711-721.
  28. Mallat Z., Corbaz A., Scoazec A. et al. Expression of interleukin - 18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-1603.
  29. Blankenberg S., Tiret L., Bickel C. et al. Interleukin - 18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
  30. Yamashita H., Shimada K., Seki E. et al. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina. Am. J. Cardiol. 2003; 91: 133-136.
  31. Blankenberg S., Luc G., Ducimetiere P. et al. Interleukin - 18 and the risk for coronary heart disease in European men. The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459.
  32. Mallat Z., Henry P., Fressonnet R. et al. Increased plasma concentrations of interleukin - 18 in acute coronary syndromes. Heart 2002; 88: 467-469.
  33. Насонова В. А., Бунчук H. В. (ред.). Избранные лекции по клинической ревматологии: Учеб. пособие для слушателей институтов и факультетов последипломного образования. М.: Медицина; 2001.
  34. Wong С. К., Li Е. К., Lam С. W. К. Elevation of plasma interleukin - 18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000; 39: 1078-1081.
  35. Park M. C., Park Y. В., Lee S. K. Elevated interleukin - 18 levels correlated with disease activity in systemic lupus erythematosus. Clin. Rheumatol. 2004; 23: 225-229.
  36. Robak E., Robak Т., Wozniacka A. et al. Pro-inflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15) - serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 2002; 13: 364-368.
  37. Amerio P., Frezzolini A., Abeni D. et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with proinflammatory cytokines. Clin. Exp. Rheumatol. 2002; 20: 535-538.
  38. Calvani N., Richards H. В., Tucci M. et al. Up-regulation of IL-18 and predominance of a Th-1 immune response is a hallmark of lupus nephritis. Clin. Exp. Immunol. 2004; 138: 171-178.
  39. Wong С. К., Ho С. Y., Li E. K. et al. Elevated production of interleukin - 18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2002; 130: 345-351.
  40. Tso Т. K., Huang W. N., Huang H. Y., Chang С. К. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology 2006; 45: 1148-1153.
  41. Hochberg M. С. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr. and Rheum. 1997; 40: 1725-1734.
  42. Wilson W. A., Gharavi A. E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr. and Rheum. 1999; 42: 1309-1311.
  43. Bombardier C., Gladman D. D., Urowitz M. B. et al. Derivation of the SLEDAI (a disease activity index for lupus patients). Arthr. and Rheum. 1992; 35: 630-640.
  44. Gladman D. D., Ginzler E., Goldsmith С. H. et al. The development and initial validation of the Systemic Lupus Erythematosus Collaborating Clinics / American College of Reumatology damage index for systemic lupus erythematosus. Arthr. and Rheum. 1996; 39: 363-369.
  45. Kannel W. В., Castelli W. P., McNamara M. P. The coronary profile: 12-year follow-up in Framingham Study. J. Occup. Med. 1987; 9: 611-619.
  46. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106: 3143.
  47. World Health Organization. International Society of Hypertension Guidelines for management of hypertension. Guidelines Subcommittee. J. Hypertens. 1999; 17: 151-183.
  48. Перова Н. В., Косматова О. В. Простой метод оценки снижения суммарного коронарного риска при лечении гипертонии и гиперлипидемии. Кардиология 2002; 3: 23-25.
  49. Haward G., Sharrett A. R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993; 24: 1297-1304.
  50. Александрова E. H., Насонов E. Л., Ковалев В. Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клин. ревматол. 1995; 4: 35-39.
  51. Segal R., Bermas В. L., Dayan М. et al. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1 / T helper cell 2 type cytokines in disease. J. Immunol. 1997; 158: 3009-3016.
  52. Viallard J. F., Pellegrin J. L., Ranchin V. et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 1999; 115: 189-195.
  53. Aso Y., Okumura K., Takebayashi K. et al. Relationships of plasma interleukin - 18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabet. Care 2003; 26: 2622-2627.
  54. Hung J., McQuillan В. M., Chapman С. M. L. et al. Elevated interleukin - 18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1268-1273.
  55. McLachlan С. S., Chua W. C., Wong P. T. et al. Homocysteine is positively associated with cytokine IL-18 plasma levels in coronary artery bypass surgery patients. Biofactors 2005; 23: 69-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies